Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Twelve patients, ten with common variable hypogammaglobulinaemia and two with hypogammaglobulinaemia secondary to chronic lymphocytic leukaemia (CLL), have been taught to self-infuse their intravenous immunoglobulin replacement therapy. Follow-up of these patients has shown that regular self-infusion at home is feasible and safe. There have been no anaphylactic or other serious reactions. Excellent patient compliance results from greater convenience and control over their own lives, in addition to time and money saved by the hospital.


Journal article


Clin Exp Immunol

Publication Date





160 - 162


Adolescent, Adult, Agammaglobulinemia, Aged, Follow-Up Studies, Humans, Immunization, Passive, Infection, Infusions, Intravenous, Middle Aged, Pilot Projects, Self Administration